Ovid Therapeutics (OVID) Receivables (2018)
Ovid Therapeutics' (OVID) quarterly Receivables came in at $4.5 million in Q3 2018.
Powered by 
Analysis
Ovid Therapeutics (OVID) Receivables (2018) Analysis & Trends
Ovid Therapeutics (OVID) has reported Receivables for 1 consecutive years, with $4.5 million the latest figure, recorded in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 12.49 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 10.13 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 1.06 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 1.13 Bn |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | - |